ArticleMolecular cancer therapeutics2009
Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines.
Article in Molecular cancer therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 66 citations in OpenAlex.
- IgM promotes antitumor immunity to a Tn-expressing solid tumor.Journal for immunotherapy of cancer · 2026Article
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- Detection of Tn-antigen in breast and prostate cancer models by VVL-labeled red dye-doped nanoparticles.Nanomedicine (London, England) · 2024Article
- Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease.Glycobiology · 2023Review
- Targeting altered glycosylation in secreted tumor glycoproteins for broad cancer detection.Glycobiology · 2023Article
- Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.Oncogene · 2023Article
- Development of a GalNAc-Tyrosine-Specific Monoclonal Antibody and Detection of TyrosineJournal of the American Chemical Society · 2022Article
- Synthesis ofTetrahedron letters · 2021Article
- Glycosylation Changes in Prostate Cancer Progression.Frontiers in oncology · 2021Review
- Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing.Cancer immunology, immunotherapy : CII · 2018Article
- ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity.Oncology letters · 2018Article
- PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors.Cancer immunology research · 2016Article
- Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.Oncoimmunology · 2016Article
- COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.Molecular cancer · 2015Article
- Associations between ABO blood groups and biochemical recurrence after radical prostatectomy.International journal of clinical and experimental medicine · 2015Article
- Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines.MedChemComm · 2014Article
- Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.Molecular pharmaceutics · 2013Article
- Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer.Cancer immunology, immunotherapy : CII · 2013Article
- Carbohydrate microarrays.Chemical Society reviews · 2013Review
- Boosting immunity to small tumor-associated carbohydrates with bacteriophage qβ capsids.ACS chemical biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The tumor-associated Tn antigen has been investigated extensively as a biomarker and therapeutic target. Cancer vaccines containing the Tn antigen as a single tumor antigen or as a component of a polyvalent vaccine have progressed into phase I and II clinical trials. One major focus of Tn-based vaccines is the treatment of prostate cancer patients. Although expression of the antigen on prostate tumors is a critical prerequisite, previous reports investigating Tn expression in prostate tumors have produced conflicting results. Using a combination of immunohistochemistry and carbohydrate microarray profiling, we show that only 4% to 26% of prostate tumors express the Tn antigen. Based on our results, the majority of prostate cancer patients do not express the appropriate antigen. Therefore, efforts to preselect the subset of prostate cancer patients with Tn-positive tumors or apply Tn vaccines to other cancers with higher rates of antigen expression could significantly improve clinical response rates. Because conflicting information on carbohydrate expression is a general problem for the field, the approach described in this article of analyzing antigen expression with multiple antibodies and using carbohydrate microarray profiles to interpret the results will be useful for the development of other carbohydrate-based cancer vaccines and diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.